Kezar Life Sciences, Inc. (KZR): Price and Financial Metrics

Kezar Life Sciences, Inc. (KZR): $0.79

0.00 (0.30%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add KZR to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#241 of 362

in industry

KZR Price/Volume Stats

Current price $0.79 52-week high $3.13
Prev. close $0.79 52-week low $0.67
Day low $0.77 Volume 421,800
Day high $0.80 Avg. volume 699,939
50-day MA $0.89 Dividend yield N/A
200-day MA $1.15 Market Cap 57.51M

KZR Stock Price Chart Interactive Chart >


Kezar Life Sciences, Inc. (KZR) Company Bio


Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis The company was incorporated in 2015 and is headquartered in South San Francisco, California.


KZR Latest News Stream


Event/Time News Detail
Loading, please wait...

KZR Latest Social Stream


Loading social stream, please wait...

View Full KZR Social Stream

Latest KZR News From Around the Web

Below are the latest news stories about KEZAR LIFE SCIENCES INC that investors may wish to consider to help them evaluate KZR as an investment opportunity.

Bull Run Bonanza: Top 3 Penny Stocks Primed for Explosive Growth

In the labyrinth of the stock market, discovering hidden gems often promises exhilarating prospects.

Yiannis Zourmpanos on InvestorPlace | December 18, 2023

Kezar Life Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference

SOUTH SAN FRANCISCO, Calif., November 21, 2023--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that Chris Kirk, Co-founder and Chief Executive Officer, will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023, at 1:20 pm ET in Miami, FL.

Yahoo | November 21, 2023

Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., November 13, 2023--Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update

Yahoo | November 13, 2023

Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., November 03, 2023--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Compensation Committee of the company’s Board of Directors granted one employee a nonqualified stock option to purchase 50,000 shares of its common stock with an exercise price of $0.77 per share, the closing price of Kezar’s common stock on November 1, 2023, the gra

Yahoo | November 3, 2023

10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis

NEW YORK, NY / ACCESSWIRE / October 24, 2023 / The biotech sector, known for its exponential growth potential, is currently facing highly challenging market conditions. Influences like rising inflation, geopolitical tensions, and looming economic ...

Yahoo | October 24, 2023

Read More 'KZR' Stories Here

KZR Price Returns

1-mo -18.93%
3-mo -5.33%
6-mo -10.04%
1-year -68.27%
3-year -86.02%
5-year -96.00%
YTD -16.61%
2023 -86.54%
2022 -57.89%
2021 220.31%
2020 30.17%
2019 -83.01%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!